General information

The pharmacist has dispensed Intuniv® 1, 2, 3 or 4mg to the patient. The health insurer will not reimburse the cost of this prescription in full. The producer of this medicine has therefore instructed TBR Nederland to reimburse to the patient the Contribution charged.

Dose 1, 2, 3 and 4mg
Type Tablets
Active ingredient GUANFACINE

Reimbursement

Conditions

The Reimbursement Scheme Regulation of Intuniv® is limited to children and adolescents 6 to 17 years of age who are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) for whom stimulants are unsuitable, are not well tolerated or have been demonstrated that they are not effective.

The Personal Contribution that is demonstrably charged to the patient by the health insurer for Intuniv® will be fully reimbursed from 1 January 2019 with a maximum of € 250 per patient per year. He / she can claim this at TBR Nederland. 

Invoices with a date of issue in 2018 will be partially reimbursed. The patient pays € 40 of the personal contribution per pack of 28 tablets, regardless of the strength. He / she can claim the remaining costs at TBR Nederland. 

Who can submit a claim

Patients or their carer can submit a claim online for the Contribution amount they paid for Intuniv® 1, 2, 3 or 4mg. Pharmacists cannot submit claims on behalf of patients for this medicine.

From when till when can you submit a claim

For this Reimbursement Scheme no closing date has been determined yet. Receipts with an issue date till 31 December 2018 can be submitted only by post, either by the pharmacist or the patient.

Submit a claim online

Patients can claim online and will receive their reimbursement within 5 working days.

Read our tips on how to submit a claim online

Login & Submit a Claim         Open an Online Account

 

C-APROM/NL//0615 December 2018

Check your medicine expenses

Quickly check the maximum contribution you have to pay for your medicine

Check Medicine Expenses

PATIENTS CAN ONLY CLAIM THEIR PAID CONTRIBUTION, NOT THEIR EXCESS

You are currently offline. Some pages or content may fail to load.